Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluating the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for First-line Treatment of Patient With Advanced Endometrial Cancer or Sarcoma of Uterus: a Multi-center, Open-label, Randomized Controlled, Phase II Clinical Trial.

Next Previous
Search
Trial Profile

Evaluating the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for First-line Treatment of Patient With Advanced Endometrial Cancer or Sarcoma of Uterus: a Multi-center, Open-label, Randomized Controlled, Phase II Clinical Trial.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benmelstobart (Primary) ; Catequentinib (Primary) ; Carboplatin; Docetaxel; Doxorubicin; Gemcitabine; Paclitaxel
  • Indications Carcinoma; Endometrial cancer; Leiomyosarcoma; Sarcoma; Uterine cancer
  • Focus Therapeutic Use
  • Sponsors Chia Tai Tianqing Pharmaceutical Group

    • Most Recent Events

    • 21 Jul 2023 Patients with Sarcoma of Uterus are now being included in study. Doxorubicin, Gemcitabine, Docetaxel drugs has been added in this study, hence number of treatments arms has been changed to 3.
    • 17 Jul 2023 Planned number of patients changed from 69 to 79.
    • 14 Sep 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top